AC

Ascenta Capital

North America, New York, United States, New York

Description

Ascenta Capital is a private equity and venture capital firm.

Investor Profile

Ascenta Capital has made 7 investments, with 3 in the past 12 months and 86% as lead.

Stage Focus

  • Series B (57%)
  • Series C (43%)

Country Focus

  • United States (86%)
  • Canada (14%)

Industry Focus

  • Biotechnology
  • Health Care
  • Medical
  • Therapeutics
  • Pharmaceutical
  • Oncology
  • Artificial Intelligence (Ai)
  • Machine Learning
  • Software
  • Biopharma
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Ascenta Capital frequently co-invest with?

OrbiMed
North America, New York, United States, New York
Co-Investments: 4
HBM Healthcare Investments
Europe, Zug, Switzerland, Zug
Co-Investments: 2
Catalio Capital Management
North America, New York, United States, New York
Co-Investments: 2
General Catalyst
North America, Massachusetts, United States, Cambridge
Co-Investments: 2
Delos Capital
North America, New York, United States, New York
Co-Investments: 2
Woodline Partners
North America, California, United States, San Francisco
Co-Investments: 2
T. Rowe Price
North America, Maryland, United States, Baltimore
Co-Investments: 2
Bain Capital Life Sciences
North America, Massachusetts, United States, Boston
Co-Investments: 2
SR One
North America, Massachusetts, United States, Cambridge
Co-Investments: 3
Fidelity
North America, Massachusetts, United States, Boston
Co-Investments: 2

Which angels does Ascenta Capital often collaborate with?

Shared Deals: 1
WR
North America, California, United States, La Jolla
Shared Deals: 1

What are some of recent deals done by Ascenta Capital?

Alpha9 Theranostics

Vancouver, British Columbia, Canada

Alpha9 Theranostics is a biopharma company that focuses on radiotherapeutics for the treatment of solid and hematologic malignancies.

BiotechnologyMedicalProduct Research
Series COct 23, 2024
Amount Raised: $175,000,000
OrsoBio

Palo Alto, California, United States

OrsoBio is a clinical-stage biopharmaceutical company that develops therapies to treat severe metabolic disorders.

BiopharmaBiotechnologyHealth CareMedicalTherapeutics
Series BSep 6, 2024
Amount Raised: $67,000,000
Cardurion Pharmaceuticals

Boston, Massachusetts, United States

Cardurion is a cardiovascular biotechnology company developing therapeutics for the treatment of heart failure and cardiovascular diseases.

BiotechnologyHealth CareMedicalPharmaceutical
Series BJul 16, 2024
Amount Raised: $260,000,000
Odyssey Therapeutics

Cambridge, Massachusetts, United States

Odyssey Therapeutics creates precision immunomodulators and oncology medicines for patients with cancer and inflammatory diseases.

BiotechnologyHealth CareOncologyTherapeutics
Series CDec 5, 2023
Amount Raised: $101,000,000
Iambic Therapeutics

San Diego, California, United States

Iambic Therapeutics is disrupting the therapeutics landscape with its unique AI-driven drug-discovery platform.

Artificial Intelligence (AI)Machine LearningSoftwareTherapeutics
Series BOct 3, 2023
Amount Raised: $100,000,000
ADARx Pharmaceuticals

San Diego, California, United States

ADARx Pharmaceuticals is a genetic medicine company focusing on the base editing of mRNA transcripts.

BiotechnologyHealth CareMedicalPharmaceutical
Series CAug 9, 2023
Amount Raised: $200,000,000
ADARx Pharmaceuticals

San Diego, California, United States

ADARx Pharmaceuticals is a genetic medicine company focusing on the base editing of mRNA transcripts.

BiotechnologyHealth CareMedicalPharmaceutical
Series BJan 20, 2023
Amount Raised: $46,000,000